Innovative BioPharmaceutical Limited submitted its latest monthly securities report on May 31, 2024, and the report was submitted to the Hong Kong Stock Exchange and Clearing Limited on June 7, 2024. The report shows that Innovative BioPharmaceutical's statutory/registered share capital remained unchanged in May, maintaining at 5,000,000,000 shares with a par value of $0.00001 per share, totaling $50,000. As for the issued shares, it increased by 920,889 shares in May, from 1,627,101,801 shares to 1,628,022,690 shares. Regarding the share option plan, 903,000 share options in the pre-IPO stock incentive plan have been exercised, and 17,889 share options in the post-IPO employee shareholding plan were exercised, with 191,506 share options cancelled. The total amount of funds received from exercising options this month was HKD1,951,676.97. The report did not mention any information about Hong Kong depository securities and confirmed that all securities issuances have been approved by the board of directors and comply with the listing rules of the Hong Kong Exchanges and Clearing Limited.

Innovative BioPharmaceutical Limited submitted its latest monthly securities report on May 31, 2024, and the report was submitted to the Hong Kong Stock Exchange and Clearing Limited on June 7, 2024. The report shows that Innovative BioPharmaceutical's statutory/registered share capital remained unchanged in May, maintaining at 5,000,000,000 shares with a par value of $0.00001 per share, totaling $50,000. As for the issued shares, it increased by 920,889 shares in May, from 1,627,101,801 shares to 1,628,022,690 shares. Regarding the share option plan, 903,000 share options in the pre-IPO stock incentive plan have been exercised, and 17,889 share options in the post-IPO employee shareholding plan were exercised, with 191,506 share options cancelled. The total amount of funds received from exercising options this month was HKD1,951,676.97. The report did not mention any information about Hong Kong depository securities and confirmed that all securities issuances have been approved by the board of directors and comply with the listing rules of the Hong Kong Exchanges and Clearing Limited.